留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

消化系统神经内分泌癌免疫治疗研究现状

陆明,  张盼盼,  沈琳

downloadPDF
文章导航 > 罕见病研究  > 2022 >  1(1): 34-37
陆明, 张盼盼, 沈琳. 消化系统神经内分泌癌免疫治疗研究现状[J]. 罕见病研究, 2022, 1(1): 34-37. doi: 10.12376/j.issn.2097-0501.2022.01.006
引用本文: 陆明, 张盼盼, 沈琳. 消化系统神经内分泌癌免疫治疗研究现状[J]. 罕见病研究, 2022, 1(1): 34-37. doi: 10.12376/j.issn.2097-0501.2022.01.006
shu
LU Ming, ZHANG Panpan, SHEN Lin. The Advance in Research into Immunotherapy for Neuroendocrine Carcinoma of Digestive System[J]. Journal of Rare Diseases, 2022, 1(1): 34-37. doi: 10.12376/j.issn.2097-0501.2022.01.006
Citation: LU Ming, ZHANG Panpan, SHEN Lin. The Advance in Research into Immunotherapy for Neuroendocrine Carcinoma of Digestive System[J]. Journal of Rare Diseases, 2022, 1(1): 34-37. doi: 10.12376/j.issn.2097-0501.2022.01.006
shu

消化系统神经内分泌癌免疫治疗研究现状

doi: 10.12376/j.issn.2097-0501.2022.01.006

  • 北京大学肿瘤医院暨北京市肿瘤防治研究所，恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142

详细信息
    通信作者:

    沈琳，E-mail: shenlin@bjmu.edu.cn

  • 中图分类号: R735;R979.1

The Advance in Research into Immunotherapy for Neuroendocrine Carcinoma of Digestive System

  • Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China

More Information

    摘要
  • 摘要: 神经内分泌肿瘤是少见的异质性肿瘤，不同病理类型、分化程度、分级和分期，治疗和转归存在很大差异。其中晚期神经内分泌癌恶性度高、预后差、可选药物较少、缺乏有效治疗手段。免疫治疗是近几年肿瘤治疗领域的最重要的突破，在多种实体瘤中显示出较好疗效。以程序性死亡受体1及其配体(programmed cell death 1/programmed cell death-ligand 1, PD-1/PD-L1)单抗为代表的免疫治疗在神经内分泌癌治疗中的作用，国内外也进行了大量探索性研究，这些研究结果对目前免疫治疗在神经内分泌癌临床应用提供了指导，也为未来相关研究开展提供了重要参考。本文对该领域的主要研究数据进行了总结和分析。

     

    Abstract: Gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) is a rare heterogeneous tumor. The heterogeneity in pathology, differentiation, grade and clinical stages results in different prognosis and treatment strategy. Patients with recurrent or metastatic NEN have limited treatment options and poor prognosis.Programmed cell death 1(PD-1) blockade has played indispensable roles in management of cancers recently.Immunotherapy is being explored in NENs in the world with emerging clinical trials. The results of the trials provide evidence and guidance in the application of NEC.The article analizes and summarizes of the findings of major investigations in this field.

     

    • HTML全文
    • 参考文献(10)
  • [1] Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma[J]. N Engl J Med, 2016, 374: 2542-2552. doi: 10.1056/NEJMoa1603702
    [2] Kaufman HL, Russell JS, Hamid O, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial[J]. J Immunother Cancer, 2018, 6: 7. doi: 10.1186/s40425-017-0310-x
    [3] Yao J, Strosberg J, Fazio N, et al. 1308O Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)[J]. Ann Oncol, 2018, 29(suppl 8): mdy293. 001.
    [4] Lu M, Zhang P, Zhang Y, et al. Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial[J]. Clin Cancer Res, 2020, 26: 2337-2345. http://www.researchgate.net/publication/339418349_Efficacy_Safety_and_Biomarkers_of_Toripalimab_in_Patients_with_Recurrent_or_Metastatic_Neuroendocrine_Neoplasms_A_Multiple-Center_Phase_Ib_Trial
    [5] Rodriguez-Freixinos V, Chan D, Doherty M, et al. Avelu-mab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)[C]. ENETS 2020, Abstract 109.
    [6] Patel SP, Othus M, Chae YK, et al. A Phase Ⅱ Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Non-Pancreatic Neuroendocrine Tumors[J]. Clin Cancer Res, 2020, 26: 2290-2296. doi: 10.1158/1078-0432.CCR-19-3356
    [7] Girard N, Mazieres J, Otto J, et al. Nivolumab (nivo) +/- ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)[J]. Ann Oncol, 2021, 32: S1318-S1318. doi: 10.1016/j.annonc.2021.08.2119
    [8] Capdevila J, Teule A, López C, et al. A multi-cohort phase Ⅱ study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)[J]. 2020 ESMO, Abstract 1157O.
    [9] Liu SV, Reck M, Mansfield AS, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)[J]. J Clin Oncol, 2021, 39: 619-630. doi: 10.1200/JCO.20.01055
    [10] Lu M, Cao Y, Gong J, et al. A Phase Ⅰ Trial of Surufa-tinib plus Toripalimab in Patients with Advanced Solid Tumor[C]. 2020 AACR Annual Meeting, Abstract 9563.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击扫码阅读文章
计量
  • 文章访问数:  2633
  • HTML全文浏览量:  166
  • PDF下载量:  167
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-12-13
  • 修回日期:  2022-01-05

目录

    /

    返回文章
    返回
    友情链接 国家卫生健康委 北京协和医院 中国罕见病联盟 中国医学科学院 学术不端检测系统 中国知网 万方数据库 术语在线 中图分类号查询

    地址: 北京市朝阳区建外SOHO东区4号楼

    电话:010-85893835E-mail: jrd@chard.org.cn

    期刊网站设计: ©罕见病研究京ICP备20001776号-1

    官方公众号

    官方微信

    RSS 邮箱订阅

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《罕见病研究》编辑部接到作者反映，有多名不法人员冒充期刊编辑通过邮箱或者短信发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱：jrd@chard.org.cn，编辑部电话：010-85893835，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！